Key Points. COVID-19 convalescent plasma (CP) may be a safe and effective treatment option in SARS-CoV-2 infection refractory to remdesivir.Infants may benefit
In this retrospective study, CAR T-cells remained effective in relapsed/refractory LBCL patients after prior exposure to bispecific antibodies (BsAbs) targ
Key Points. Molecular MRD after induction chemotherapy identifies patients with NPM1 AML who benefit from allogeneic transplant in first remissionPatients
In this issue of Blood, Woyach et al1 report an update of a pivotal phase 3 trial showing the superiority of ibrutinib (Ibr)-based treatments over chemoimm
A 63-year-old man presented with fever, splenomegaly, hyperferritinemia (10 798 ng/dL), elevated soluble interleukin-2R (6644 pg/mL), anemia (hemoglobin 6.9 g/dL), and thrombocytopenia (42 000/μL). Atypical…
In this issue of Blood, Woyach et al1 report an update of a pivotal phase 3 trial showing the superiority of ibrutinib (Ibr)-based treatments over chemoimm
In this issue of Blood, Gerds et al identified persistent leukocytosis above the upper normal value as a risk factor for thrombosis in polycythemia vera. F
Key Points. RAS/RAF mutations are present in up to 61% of patients with multiple myelomaMost of them are subclonal, in agreement with a secondary event
